SNSE
NASDAQSensei Biotherapeutics Inc.
Price$13.91-17.13 (-55.18%)
2026-03-122026-06-15
News · 26 weeks72+25%
2026-03-012026-08-23
Mix3990d
- Insider19(49%)
- SEC Filings12(31%)
- Other6(15%)
- Analyst2(5%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Sensei Biotherapeutics Inc.SCHEDULE 13G/A - Faeth Therapeutics, Inc. (0001829802) (Subject)
- SECSEC Form SCHEDULE 13G filed by Sensei Biotherapeutics Inc.SCHEDULE 13G - Faeth Therapeutics, Inc. (0001829802) (Subject)
- SECSEC Form 144 filed by Sensei Biotherapeutics Inc.144 - Faeth Therapeutics, Inc. (0001829802) (Subject)
- SECSEC Form 10-Q filed by Sensei Biotherapeutics Inc.10-Q - Faeth Therapeutics, Inc. (0001829802) (Filer)
- SECSensei Biotherapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Faeth Therapeutics, Inc. (0001829802) (Filer)
- INSIDERNew insider Khosla Ventures Vi, L.P. claimed ownership of 2,632,232 shares (SEC Form 3)3 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- SECSEC Form 8-K filed by Sensei Biotherapeutics Inc.8-K - Faeth Therapeutics, Inc. (0001829802) (Filer)
- INSIDERSEC Form 4 filed by President and CEO Parikh Anand Kiran4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 4 filed by PAO Craver Josiah4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- INSIDERChief Financial Officer Stephenson Brian C bought $326,127 worth of shares (13,634 units at $23.92) (SEC Form 4)4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- INSIDERChief Financial Officer Stephenson Brian C bought $401,269 worth of shares (15,641 units at $25.65) (SEC Form 4)4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- INSIDERChief Financial Officer Stephenson Brian C bought $405,921 worth of shares (17,413 units at $23.31) (SEC Form 4)4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- INSIDERPresident and CEO Parikh Anand Kiran bought $55,447 worth of shares (2,806 units at $19.76) and exercised 53,465 shares at a strike of $1.16, increasing direct ownership by 7% to 817,699 units (SEC Form 4)4 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 3 filed by new insider Stephenson Brian C3 - Faeth Therapeutics, Inc. (0001829802) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Sensei Biotherapeutics Inc.SCHEDULE 13G - Faeth Therapeutics, Inc. (0001829802) (Subject)
- SECSEC Form 8-K filed by Sensei Biotherapeutics Inc.8-K - Faeth Therapeutics, Inc. (0001829802) (Filer)
- SECSEC Form S-3ASR filed by Sensei Biotherapeutics Inc.S-3ASR - Faeth Therapeutics, Inc. (0001829802) (Filer)
- INSIDERSEC Form 4 filed by Director Ramasastry Saira4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERPresident and CEO Parikh Anand Kiran converted options into 761,428 shares (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 3 filed by new insider Ramasastry Saira3 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERDirector Hahn Stephen M. converted options into 44,763 shares (SEC Form 4)4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERSEC Form 3 filed by new insider Hahn Stephen M.3 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by President and CEO Parikh Anand Kiran4/A - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
- SECSensei Biotherapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- PRSensei Biotherapeutics Announces Name Change to Faeth Therapeutics, Focused on Advancing PIKTOR, an Oral Therapy Targeting One of the Most Frequently Altered Pathways in Cancer— Stockholders approved conversion of the Series B preferred stock issued in the February 2026 acquisition of Faeth Therapeutics and concurrent private placement — — Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock expected to begin trading under the ticker symbol "FTH" on June 16, 2026 — — Anand Parikh, Faeth co-founder, appointed Chairman, President and Chief Executive Officer; Brian Stephenson, Ph.D., CFA appointed Chief Financial Officer; board strengthened with the addition of former FDA Commissioner Stephen M. Hahn, M.D., and Saira Ramasastry — — PIKTOR, an investigational all-oral multi-node inhibitor of the PI3K/AKT/mTOR pathway, on track for top
SNSE FAQ
7 questionsWhat does Sensei Biotherapeutics Inc. do?
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei...Where does SNSE stock trade?
Sensei Biotherapeutics Inc. (SNSE) is listed on NASDAQ.What sector and industry is SNSE in?
Sensei Biotherapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sensei Biotherapeutics Inc. go public?
Sensei Biotherapeutics Inc. (SNSE) completed its IPO in 2021.What are analysts saying about SNSE?
Sensei Biotherapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from BTIG Research: Buy on 2026-06-11. Recent price targets range from $500.00 to $1200.00.What companies are similar to SNSE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SNSE side-by-side with any of them on Quantisnow.How can I track SNSE on Quantisnow?
Quantisnow aggregates Sensei Biotherapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SNSE to receive live email and push alerts on every new disclosure.